Orally-administered caspase inhibitor PF-03491390 is retained in the liver for prolonged periods with low systemic exposure, exerting a hepatoprotective effect against alpha-fas-induced liver injury in a mouse model (Q46956372)
Jump to navigation
Jump to search
scientific article published on 6 October 2007
Language | Label | Description | Also known as |
---|---|---|---|
English | Orally-administered caspase inhibitor PF-03491390 is retained in the liver for prolonged periods with low systemic exposure, exerting a hepatoprotective effect against alpha-fas-induced liver injury in a mouse model |
scientific article published on 6 October 2007 |
Statements
1 reference
Orally-administered caspase inhibitor PF-03491390 is retained in the liver for prolonged periods with low systemic exposure, exerting a hepatoprotective effect against alpha-fas-induced liver injury in a mouse model (English)
1 reference
Yoshinobu Ueno
1 reference
Takashi Ohmi
1 reference
Mitsuko Yamamoto
1 reference
Naoto Kato
1 reference
Yukiko Moriguchi
1 reference
Midori Kojima
1 reference
Rieko Shimozono
1 reference
Sachiko Suzuki
1 reference
Tomomi Matsuura
1 reference
Hiroyuki Eda
1 reference
6 October 2007
1 reference
105
1 reference
2
1 reference
201-205
1 reference